Vijaya Diagnostic Centre Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Thu Apr 30 2026

Vijaya Diagnostic Centre (NSE: VIJAYA) is set to announce its Q4 FY26 financial results for the quarter and full year ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited financial statements and consider a recommendation for a final dividend for FY26. Investors tracking the Vijaya Diagnostic Centre Q4 results 2026 date, earnings estimates, and analyst outlook will find all the key details in this article.

With Vijaya Diagnostic Centre trading at a current market price of Rs 780 against a 52-week high of Rs 1250 and a 52-week low of Rs 590, the Q4 FY26 results will be a pivotal data point for investors. Analyst estimates for Q4 FY26 revenue stand at Rs 198 to 218 Cr, with PAT expectations of Rs 46 to 54 Cr and margin projections of 23 to 26%. Get free investment predictions and live Q4 result alerts on Univest.

This article covers the Vijaya Diagnostic Centre Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.

Table of Contents

Vijaya Diagnostic Centre Q4 Results 2026 Date

Get free investment predictions on Univest.

Vijaya Diagnostic Centre has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet to approve the audited consolidated financial statements for the quarter and full year ended March 31, 2026. The trading window for designated employees is closed until 48 hours after the results announcement, as per SEBI regulations.

Company	Q4 FY26 Results Date
TCS	April 9, 2026 (Declared)
Vijaya Diagnostic Centre	May 2026 (Expected)

Source: BSE/NSE exchange filings, April 2026. Expected dates may change. Verify before relying.

Why This Quarter Matters for Vijaya Diagnostic Centre

Vijaya Diagnostic Centre enters Q4 FY26 with expectations of meaningful year-on-year improvement in its core Diagnostic Healthcare Pathology business. Q4 is typically a seasonally important quarter as companies execute on year-end targets, government orders pick up, and annual dividend recommendations are made. For Vijaya Diagnostic Centre specifically, Q4 FY26 matters because it sets the baseline for FY27 estimates and determines full-year FY26 performance.

Every quarterly result tells a story, but Vijaya Diagnostic Centre’s Q4 FY26 print will be watched closely because it sets the baseline for FY27 estimates, determines full-year FY26 performance, and provides the first clear read on whether business momentum is accelerating or decelerating. Management guidance on margins, volumes, and capital allocation will be just as important as the headline PAT number. Screen Vijaya Diagnostic Centre fundamentals on the Univest Screener.

Vijaya Diagnostic Centre Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Brokerages including MOFSL, YES Securities, JM Financial, and others have published their Q4 FY26 preview estimates for Vijaya Diagnostic Centre. The consensus expects Rs 198 to 218 Cr in revenue for Q4 FY26, compared to Rs 185 Cr in Q3 FY26. Profit after tax (PAT) is estimated at Rs 46 to 54 Cr, with margin expectations of 23 to 26%.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate	YoY Trend
Revenue	Rs 185 Cr	Rs 198 to 218 Cr	Sequential growth expected
PAT (Net Profit)	Rs 42 Cr	Rs 46 to 54 Cr	Improvement anticipated
EBITDA Margin	22.7%	23 to 26%	Stable to marginal improvement
Revenue Growth Driver	Core business execution	Seasonal uptick plus order execution	Positive
Dividend Expectation	As per FY26 policy	Final dividend possible	Board discretion

Vijaya Diagnostic Centre enters Q4 FY26 with expectations of Rs 198 to 218 Cr in revenue driven by execution on existing orders and seasonal demand pickup. Management commentary on the pipeline and deal wins will set the direction for FY27 estimates. Screen Vijaya Diagnostic Centre fundamentals on the Univest Screener.

5 Key Factors That Will Drive Vijaya Diagnostic Centre Q4 FY26 Performance

1. Revenue Execution and Order Book Conversion

Vijaya Diagnostic Centre enters Q4 FY26 with a focus on executing on its existing order book and converting pipeline into recognised revenue. Q4 is seasonally important for the Diagnostic Healthcare Pathology sector and the ability to deliver on committed orders will be the first performance test. Analysts expect Rs 198 to 218 Cr in revenue for Q4 FY26. A beat here would signal improving execution capability and set a strong base for FY27 guidance. Track live revenue updates on the Univest Screener.

2. Margin Recovery and Cost Control

Q4 FY26 margin expectations are 23 to 26% versus 22.7% in Q3 FY26. Input cost trends, employee expense efficiency, and pricing power in key markets will collectively determine whether Vijaya Diagnostic Centre can sustain or improve on Q3 margins. Any margin beat here would be a meaningful positive catalyst for the stock and for FY27 earnings visibility.

3. Final Dividend and Capital Allocation Signals

Q4 board meetings are typically when companies announce their final dividend for the fiscal year. Vijaya Diagnostic Centre’s capital allocation stance, including whether it maintains, increases, or skips the final dividend, will signal management confidence in the business outlook. A higher-than-expected dividend payout would be a positive surprise for income-focused investors tracking the Vijaya Diagnostic Centre Q4 results 2026.

4. FY27 Management Guidance

Investors should monitor revenue versus Rs 198 to 218 Cr and PAT versus Rs 46 to 54 Cr as the two primary watchpoints. If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. Forward guidance carries more weight than the reported quarter in the current environment. Get SEBI-registered research on Univest.

5. Sector Tailwinds and Macro Environment

The Diagnostic Healthcare Pathology sector in India is benefiting from structural demand drivers including government capex, domestic consumption recovery, and a supportive policy environment. Vijaya Diagnostic Centre’s ability to translate these sector tailwinds into quarterly earnings growth will be closely watched by institutional investors. The RBI rate cut cycle that commenced in 2026 has also reduced borrowing costs across the sector, providing a further boost to profitability.

5 Risks to Watch in Vijaya Diagnostic Centre Q4 FY26

1. Revenue Miss Risk

If revenue comes in below the Rs 198 to 218 Cr estimate range, it would signal execution challenges in the Diagnostic Healthcare Pathology business. A miss at the revenue line typically triggers a cascading impact on PAT and margin, amplifying the negative reaction in the stock price.

2. FII Selling Pressure

FIIs sold Rs 22,000 crore in Indian equities in a single week following the US tariff announcement in early April 2026. Continued selling would create headwinds for Vijaya Diagnostic Centre regardless of company-specific fundamentals. With global risk appetite still cautious, institutional positioning remains a key external risk for the stock heading into Q4 results.

3. Margin Compression Risk

Input cost inflation, wage increases, and pricing pressure in key markets could compress Vijaya Diagnostic Centre’s margins below the 23 to 26% estimate. Any margin miss combined with a revenue miss creates a double negative that typically leads to sharp post-results corrections. Monitor margin trends on the Univest Screener.

4. Regulatory and Policy Risks

The Diagnostic Healthcare Pathology sector faces evolving regulatory frameworks. Policy changes that increase compliance costs or alter competitive dynamics could affect Vijaya Diagnostic Centre’s profitability beyond current consensus models. Any negative regulatory development announced alongside the Q4 results could weigh on investor sentiment.

5. Weak FY27 Guidance Risk

Even if Q4 FY26 numbers come in line with estimates, a below-consensus FY27 guidance from management would be the single biggest negative catalyst. The market prices stocks on forward earnings, and a guidance cut would compress the valuation multiple applied to Vijaya Diagnostic Centre’s earnings, pushing the stock lower despite an acceptable reported quarter.

Vijaya Diagnostic Centre Share Price and Analyst Ratings

Vijaya Diagnostic Centre is trading at Rs 780 as of April 2026, against a 52-week high of Rs 1250 and 52-week low of Rs 590. The stock has a market capitalisation of approximately Rs 7200 Cr. Download the Univest iOS App or Univest Android App for live Vijaya Diagnostic Centre Q4 result alerts and SEBI-registered research.

Brokerage	Rating	Target Price	Key Thesis
MOFSL	Buy	Rs 1000	Vijaya Diagnostic Centre Diagnostic Healthcare Pathology sector growth outlook FY27
YES Securities	Buy	Rs 975	Vijaya Diagnostic Centre Diagnostic Healthcare Pathology sector growth outlook FY27
Emkay	Neutral	Rs 940	Vijaya Diagnostic Centre Diagnostic Healthcare Pathology sector growth outlook FY27

Conclusion

Vijaya Diagnostic Centre Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Diagnostic Healthcare Pathology sector. Analysts project PAT of Rs 46 to 54 Cr and revenue of Rs 198 to 218 Cr. FY27 guidance will be the most critical post-results catalyst alongside the headline Q4 numbers. For more Q4 FY26 previews, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Frequently Asked Questions

What is the Vijaya Diagnostic Centre Q4 results 2026 date?

The Vijaya Diagnostic Centre Q4 results 2026 date is May 2026 (Expected). The board of directors will meet on this date to approve the audited financial results for the quarter and full year ended March 31, 2026.

What is the Vijaya Diagnostic Centre Q4 FY26 PAT estimate?

Analyst consensus estimates Vijaya Diagnostic Centre Q4 FY26 PAT at Rs 46 to 54 Cr, based on revenue of Rs 198 to 218 Cr and margin of 23 to 26%. The actual number will be declared on May 2026 (Expected).

What is Vijaya Diagnostic Centre’s share price ahead of Q4 results?

Vijaya Diagnostic Centre is trading at Rs 780 ahead of Q4 FY26 results. The 52-week high is Rs 1250 and the 52-week low is Rs 590. The market cap is approximately Rs 7200 Cr. Track live price on the Univest Screener.

Will Vijaya Diagnostic Centre declare a dividend in Q4 2026?

The Vijaya Diagnostic Centre board may consider a final dividend for FY26 at its Q4 results board meeting on May 2026 (Expected). Dividend decisions are at board discretion and depend on the company’s profitability and cash flow position for the full year. Track dividend announcements on NSE or the Univest Screener.

Which analysts have a Buy rating on Vijaya Diagnostic Centre?

MOFSL (Target: Rs 1000), YES Securities (Target: Rs 975). Analyst ratings and target prices change frequently. Always verify the latest ratings on the Univest Screener.

What were Vijaya Diagnostic Centre Q3 FY26 results?

Vijaya Diagnostic Centre reported revenue of Rs 185 Cr and PAT of Rs 42 Cr in Q3 FY26, with an operating margin of 22.7%. The Q4 FY26 results on May 2026 (Expected) will provide the next quarterly update. Get detailed financial analysis on Univest.

When does TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Find the full TCS Q4 FY26 analysis on Univest Blogs.

Is Vijaya Diagnostic Centre a good investment ahead of Q4 results?

Whether Vijaya Diagnostic Centre is a good investment ahead of Q4 FY26 results depends on your investment horizon and risk appetite. At Rs 780, the stock is trading at a discount to its 52-week high of Rs 1250. Analyst consensus targets range from Rs 940 to Rs 1000. Always consult a SEBI-registered financial advisor before making any investment decision. Get free research on Univest.